DK3129378T3 - Bromdomæne-hæmmende forbindelser og farmaceutisk sammensætning omfattende disse til forebyggelse eller behandling af en cancer - Google Patents

Bromdomæne-hæmmende forbindelser og farmaceutisk sammensætning omfattende disse til forebyggelse eller behandling af en cancer Download PDF

Info

Publication number
DK3129378T3
DK3129378T3 DK15776821.9T DK15776821T DK3129378T3 DK 3129378 T3 DK3129378 T3 DK 3129378T3 DK 15776821 T DK15776821 T DK 15776821T DK 3129378 T3 DK3129378 T3 DK 3129378T3
Authority
DK
Denmark
Prior art keywords
broomdomene
relations
inhibiting
cancer
prevention
Prior art date
Application number
DK15776821.9T
Other languages
English (en)
Inventor
Su-Sung Oh
Minjeong Choi
Original Assignee
Kainos Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kainos Medicine Inc filed Critical Kainos Medicine Inc
Application granted granted Critical
Publication of DK3129378T3 publication Critical patent/DK3129378T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK15776821.9T 2014-04-09 2015-04-08 Bromdomæne-hæmmende forbindelser og farmaceutisk sammensætning omfattende disse til forebyggelse eller behandling af en cancer DK3129378T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977370P 2014-04-09 2014-04-09
PCT/KR2015/003530 WO2015156601A1 (en) 2014-04-09 2015-04-08 Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer

Publications (1)

Publication Number Publication Date
DK3129378T3 true DK3129378T3 (da) 2019-10-07

Family

ID=54288110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15776821.9T DK3129378T3 (da) 2014-04-09 2015-04-08 Bromdomæne-hæmmende forbindelser og farmaceutisk sammensætning omfattende disse til forebyggelse eller behandling af en cancer

Country Status (9)

Country Link
US (1) US9884874B2 (da)
EP (1) EP3129378B1 (da)
JP (1) JP6333996B2 (da)
KR (1) KR101928521B1 (da)
CN (1) CN106132968B (da)
DK (1) DK3129378T3 (da)
ES (1) ES2751642T3 (da)
PL (1) PL3129378T3 (da)
WO (1) WO2015156601A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN107629057B (zh) * 2016-07-19 2020-03-27 上海勋和医药科技有限公司 Bet蛋白抑制剂及其应用
WO2018109053A1 (en) * 2016-12-16 2018-06-21 F. Hoffmann-La Roche Ag Process for the manufacture of diazepine derivatives
CN112312916A (zh) 2018-06-13 2021-02-02 戴布里股份公司 缩合三氮杂卓衍生物的制备及其作为bet抑制剂的用途
CN114702451B (zh) * 2022-03-29 2024-05-14 国药集团国瑞药业有限公司 一种氯硝西泮及其中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120939A1 (en) * 1991-10-11 1993-04-15 Tetsuya Tahara Therapeutic agent for osteoporosis and diazepine compound
EP0661284A1 (en) 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
AU2008313467B2 (en) 2007-10-17 2013-08-29 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one
CN101910182B (zh) * 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
CN102781943B (zh) * 2009-11-05 2016-10-05 葛兰素史密丝克莱恩有限责任公司 苯并二氮杂*溴结构域抑制剂
GB0919426D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
DK2496580T3 (da) 2009-11-05 2014-02-24 Glaxosmithkline Llc Benzodiazepinbromdomænehæmmer
EP2569429A4 (en) 2010-05-14 2013-09-25 Dana Farber Cancer Inst Inc COMPOSITIONS AND METHOD OF METABOLIC MODULATION
AU2011252808B2 (en) 2010-05-14 2015-05-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013033268A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same

Also Published As

Publication number Publication date
PL3129378T3 (pl) 2020-03-31
JP6333996B2 (ja) 2018-05-30
EP3129378A1 (en) 2017-02-15
JP2017510605A (ja) 2017-04-13
WO2015156601A1 (en) 2015-10-15
CN106132968B (zh) 2019-04-05
KR101928521B1 (ko) 2018-12-13
EP3129378A4 (en) 2017-08-23
EP3129378B1 (en) 2019-06-26
KR20160133006A (ko) 2016-11-21
CN106132968A (zh) 2016-11-16
US9884874B2 (en) 2018-02-06
US20170174702A1 (en) 2017-06-22
ES2751642T3 (es) 2020-04-01

Similar Documents

Publication Publication Date Title
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3227262T3 (da) Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3380101T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3152291T3 (da) Fremgangsmåder og indretninger til kapillar-understøttet vitrificering
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3183010T3 (da) Anordning og tilhørende fremgangsmåde til behandling af medicinsk affald
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme